The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 02, 2014
Filed:
Nov. 24, 2010
William C. Olson, Ossining, NY (US);
Paul J. Maddon, Scarsdale, NY (US);
Daniel C. Pevear, Medford, MA (US);
Robert J. Israel, Suffern, NY (US);
Jose D. Murga, Rosedale, NY (US);
William C. Olson, Ossining, NY (US);
Paul J. Maddon, Scarsdale, NY (US);
Daniel C. Pevear, Medford, MA (US);
Robert J. Israel, Suffern, NY (US);
Jose D. Murga, Rosedale, NY (US);
CytoDyn Inc., Vancouver, WA (US);
Abstract
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.